{"analyses":[{"ciLowerLimit":"0.05","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.56","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0010","paramType":"Hazard Ratio (HR)","paramValue":"0.16","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"IBR: Median OS was not reached so 95% CI for median OS is not applicable.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"CHL: Median OS was not reached so 95% CI for median OS is not applicable.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ibrutinib 420 mg daily.","id":"OG000","title":"Ibrutinib"},{"description":"Chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) days 1 and 15 of 28-day cycle up to 12 cycles","id":"OG001","title":"Chlorambucil"}],"paramType":"MEDIAN","populationDescription":"Intention to treat","reportingStatus":"POSTED","timeFrame":"Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}